NeoStem Announces BioProcess International Excellence in Leadership Award Given to Dr. Robert Preti, Chief Scientific Officer and President of PCT
NeoStem Announces USAN Approval of Generic Name ‘Eltrapuldencel-T’ for Investigational Patient-Specific Targeted Cancer Immunotherapy
Dr. Robin Smith, CEO of NeoStem, discusses how the acquisition of six biotech companies has enabled her to find talent in the emerging industry of cell therapy.
Finance Monthly interviews NeoStem CEO Dr. Robin L. Smith about current programs and what the future might hold.
Dr. Robin Smith discusses NeoStem and its platform technologies with Pimm Fox, anchor of Taking Stock on Bloomberg Radio.
© 2014 Bloomberg L.P. All rights reserved. Used with permission.
NeoStem’s Investigational Targeted Cancer Immunotherapy For Late Stage Melanoma (2 minute)
See how NeoStem's Phase III investigational targeted cancer immunotherapy, NBS20 (eltrapuldencel-T), is created and administered. The product candidate is being evaluated for the treatment of patients suffering from late stage malignant melanoma.